Genitourinary Oncology, Associate Professor, Vanderbilt University Vice President, MRD Research and Clinical Strategy, Tempus AI
Nashville, TN
Joined June 2009
- Tweets3.7K
- Following1.8K
- Followers2.3K
- Likes2.5K
Pinned Tweet
Thanks @CureMelanoma for the opportunity to discuss ctDNA in #melanoma, also thanks to my son Auguste for the #cameo appearance! – at Chicago, IL
JNJ-87189401 + pasritamig at #SITC26, presented by @LauraGrahamMD. Phase 1 RP2R in pretreated mCRPC (n=15):
▪️ PSA50 73%, PSA90 47%
▪️ Undetectable PSA 27%, ongoing >6 mo
▪️ CRS 20% all G1; no G3+ TRAEs
@OncLive @OncoAlert @UroToday #ProstateCancer
onclive.com/view/jnj-8718940…
Alan Tan retweeted
📣 another FDA approval in APMS
➡️ MANY in 2026 inc. pluvicto & capivasertib
➡️ now talazoparib/enza vs enza #TALAPRO3 for HRR-altered APMS (vs AMPLITUDE only BRCA2)
➡️ rPFS 77% vs 56% (HR 0.48)
⚠️ OS immature, G≥3 anemia 51%, 40% transfused; no docetaxel-triplet comparator
Alan Tan retweeted
Happy to have presented "Optimal induction treatment in non-metastatic bladder cancer" at #ESMO26 Madrid! Big thanks to the fantastic panel! @MichvdHeijden @giannatempopatr @LAUrology_NL
Main message: deeper response = greater benefit. EV-based induction moves pCR most – and VOLGA suggests less EV may be enough!
@OncoAlert @weoncologists @urotoday @Uromigos
@OncoAlert and Faculty: @DrChoueiri @tompowles1 @apolo_andrea @neerajaiims @montypal @Silke_Gillessen @AOmlin @brian_rini @PGrivasMDPhD @TiansterZhang @amerseburger @DrDanielHeng @HHammersMD @scocmem @AndreaNecchi @AmandaNizamMD @drenriquegrande @nataliagandur @AlbigesL @cdanicas @declangmurphy @seanmmcbride @shilpaonc @DrRanaMcKay @scserendipity1 @DrYukselUrun @ravikanesvaran @BraunMDPhD @EfstathiouEleni @mzugman @crisbergerot @Markuseckstein3
Alan Tan retweeted
The first time I came across Dr. Weber's name was when I read the #CheckMate238 trial. I then googled his name to learn more about him and found out he had worked at Moffitt Cancer Center, where I am currently working, before joining NYU Langone Health. Then, I read
Alan Tan retweeted
Superb presentation by our very own @DanaFarber_GU @VincentWenxinXu! COSMIC-313: a ≥30% plasma KIM-1 decline at week 3 on nivo/ipi was associated with median PFS of 41.6 vs 8.3 months without that decline. An early blood-based window into treatment response! #ESMO26 @oncoalert @myESMO @DanaFarber
Alan Tan retweeted
LITESPARK-12 tested Len/pem/CTLA4 vs Len/pem in 1st line advanced RCC. This, and the adjuvant nivo vs ipi/nivo trials both add CTLA4 to Nivo. #ESMO26 8Y8 (ipi/nivo vs Nivo) is long awaited. Uncertainty on the role of CTLA4 is increasingly uncertain @brian_rini @DrChoueiri @OncoAlert
Alan Tan retweeted
🚨 PEACE-1: 8y FU long-term analysis
In patients receiving ADT+docetaxel (n=710), adding abiraterone delivers:
🔹mOS: 6.2 vs 4.4 years (HR 0.68)
🔹 8-yOS: 40.3% vs 27.1%
🔹 High-vol OS: HR 0.67
🔹 Low-vol OS: HR 0.74
🔹 No treatment-by-volume interaction (P=0.5552).
@OncoAlert
Alan Tan retweeted
LITESPARK-12 tested Len/pem/bel (VEGF/PD1/HIF) vs Len/pem in 1st line RCC #ESMO26 (supported by a RII +ve PFS R2 @AlbigesL @crisuarez08). In the R3 both PFS and OS hasd HRs~1 with ⬆️ tox for triplets. Belzutifan doublets seem active so why do the triplets fail. It’s likely due to the increased toxic compromising dose intensity of the extremely active Len/pem (2 yr PFS). There seems a limit to tolerable drug intensity- triplets (COSMIC313 too) maybe a step too far. @OncoAlert @DrChoueiri
Alan Tan retweeted
This is a game changer!!
45% durable ORRs at higher dose levels.
READY for prime time and will change early treatment lines.
As excited as when I first saw PD1 results in RCC.
This will transform front lines and cure more patients.
OncoAlert #Podium2Screen🚨 #ESMO26
XmAb819 in #RCC
Our @OncoAlert founding faculty @montypal 🇺🇸presents a first-in-class ENPP3 x CD3 bispecific in heavily pretreated ccRCC:
➡️ ORR 27%, DCR 68%
➡️ Activity after prior HIF-2α inhibitor (ORR 26%)
➡️ 15/16 responders still on treatment
#KidneyCancer
@AlbigesL, @MehmetAsimBilen
Pinging Our Faculty
@DrChoueiri, @tompowles1, @apolo_andrea, @neerajaiims, @montypal, @Silke_Gillessen, @AOmlin, @brian_rini, @PGrivasMDPhD, @TiansterZhang, @amerseburger, @DrDanielHeng, @HHammersMD, @scocmem, @AndreaNecchi, @AmandaNizamMD, @drenriquegrande, @nataliagandur, @AlbigesL, @cdanicas, @declangmurphy, @seanmmcbride, @shilpaonc, @DrRanaMcKay, @scserendipity1, @DrYukselUrun, @ravikanesvaran, @BraunMDPhD, @EfstathiouEleni, @mzugman, @crisbergerot, @niklas_kluemper @Markuseckstein3
Alan Tan retweeted
💔 EV has a new partner!
PEMBRO: “Another checkpoint inhibitor?!” 😳
EV: “We have survival data TOO!” ❤️
🔥 VOLGA | ESMO 2026
EFS HR 0.51 | OS HR 0.58
But PEMBRO isn't out of the picture!
KEYNOTE-905: EFS HR 0.40 | OS HR 0.50
Two promising perioperative partnerships in cisplatin-ineligible MIBC.
⚠️ Different trials. No head-to-head comparison.
@myESMO @OncoAlert #MVOnco #ESMO2026 #BladderCancer
Alan Tan retweeted
1/n Major congrats to our DASL team, especially to @ChrisSweens1 and @niazi_Dr7, and a big thanks to the patients. Working with @ANZUPtrials and @ThePCCTC on DASL as US lead has been a career highlight.
I'd contend this establishes a new standard of care in DASL very-high risk PCa. The conventional-image defined MFS benefit with the addition of Darolutamide to RT+ADT was extraordinarily robust; the DSMC recommended reporting out at IA. #ESMO26, #radonc, #medtwitter. @MSKCancerCenter @MSK_RadOnc. #pcsm
Brief 🧵
DASL-HiCaP at #ESMO26, presented by @Niazi_Dr7: darolutamide + RT + 2 yrs ADT vs placebo in very high-risk prostate cancer (n=1,106)
▪️ MFS HR 0.42, 4-yr MFS 95% vs 88%
▪️ PSA-PFS HR 0.47
▪️ Time to CRPC HR 0.22
▪️ OS immature (HR 0.88)
#ProstateCancer
DASL-HiCaP at #ESMO26, presented by @Niazi_Dr7: darolutamide + RT + 2 yrs ADT vs placebo in very high-risk prostate cancer (n=1,106)
▪️ MFS HR 0.42, 4-yr MFS 95% vs 88%
▪️ PSA-PFS HR 0.47
▪️ Time to CRPC HR 0.22
▪️ OS immature (HR 0.88)
#ProstateCancer
DeLLphi-305 at #ESMO26, presented by Jacob Sands, got a standing ovation. An important advance in very aggressive biology. Tarlatamab + durvalumab vs durvalumab as 1L maintenance in ES-SCLC:
▪️ OS HR 0.42, median 21.1 vs 12.7 mo
▪️ PFS HR 0.34
▪️ ORR 26.4% vs 4.1%
Important to study in NEPC and small cell bladder.
4
432
Georgina Long presented INTerpath-001 at #ESMO26: intismeran + pembrolizumab vs placebo + pembrolizumab as adjuvant therapy for resected melanoma. It met the primary RFS endpoint (42% reduction in risk of recurrence or death) and the key secondary DMFS endpoint (38% reduction). OS is still immature, and follow-up is ongoing.
CheckMate 8HW final OS at #ESMO26: NIVO+IPI in centrally confirmed MSI-H/dMMR mCRC
▪️ All lines vs NIVO: HR 0.61 (0.46–0.82), p=0.0009; 5-yr OS 74% vs 62%
▪️ 1L vs NIVO: HR 0.66 (0.44–0.99), p=0.043, missed prespecified boundary (p<0.0058); 5-yr OS 77% vs 66%
▪️ 1L vs chemo: OS HR 0.37, p<0.0001
▪️ Median f/u ~68 mo; safety stable, low grade 3/4
#CRCSM #MSIH
204
#ESMO26 PROTEUS discussion by Nicholas van As
• No baseline PSMA PET; enrolled conventionally staged M0
• MFS events: true progression or delayed detection? Most were PSMA PET-detected (8.8% vs 16.3%)
• TTST HR 0.29, but ~20-mo lead-time bias
#ProstateCancer
PROTEUS substudy at #ESMO26 presented by Alberto Briganti 🇪🇸
Perioperative apalutamide + ADT vs RP + PLND alone in HR localized/LA prostate cancer (N=408, 1:3)
▪️ EFS HR 0.38 (0.26–0.55), p<0.0001
▪️ 36-mo EFS 63% vs 41%; SOC median EFS only 19.1 mo
▪️ Benefit held after T recovery
@neerajaiims @DrChoueiri @DrRanaMcKay @tompowles1 #ProstateCancer
